Comprehensive suite of tools for trading and investing in biotech stocks. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more
http://www.biopharmcatalyst.com/
TODAY'S RATING
#210,233
Date Range
HIGHEST TRAFFIC ON
Friday
LOAD TIME
8 seconds
16x16
32x32
ADAM BURDEN
ADAM BURDEN
103A ●●●●●LE RD
NOR●●●OTE
AUC●●●AND , AUCKLAND, 0626
NZ
View this contact
BIOPHARMCATALYST
ADAM BURDEN
103A ●●●●●LE RD
BIR●●●ALE
AUC●●●AND , 0626
NZ
View this contact
ADAM BURDEN
ADAM BURDEN
103A E●●●●●●E ROAD
NOR●●●OTE
AUC●●●AND , AUCKLAND, 0626
NZ
View this contact
BUY YOUR DOMAIN
15
YEARS
1
MONTHS
26
DAYS
ENOM, INC.
WHOIS : whois.enom.com
REFERRED : http://www.enom.com
PAGES IN
THIS WEBSITE
19
SSL
EXTERNAL LINKS
118
SITE IP
104.28.13.200
LOAD TIME
8.026 sec
SCORE
6.2
Biotech Stocks for investors and traders • BioPharmCatalyst | biopharmcatalyst.com Reviews
https://biopharmcatalyst.com
Comprehensive suite of tools for trading and investing in biotech stocks. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more
biopharmcatalyst.com
FDA Calendar | BioPharmCatalyst
https://www.biopharmcatalyst.com/fda-calendar
FDA Calendar – Glossary. 2016 Biotech Calendar and beyond for your biotech investing. Biotech Catalyst Calendar. Biotech stocks, FDA Approval/PDUFA, Advisory Committee and Phase 2 and 3 trial data releases dates. Data are current and updated daily! The BioPharmCatalyst FDA Calendar is NOT an official calendar. It has absolutely NO affiliation with the FDA. The calendar is created using company SEC filings and press releases. Note that the catalyst date is the LATEST expected date. Catalyst Date (due by).
EMA Calendar | BioPharmCatalyst
https://www.biopharmcatalyst.com/ema-calendar
FDA Calendar – Glossary. European MAA Calendar. Approval date uses 13 month estimate following filing. Review period is 210 days PLUS additional time for review/consultation. Note there is NO definitive timeframe. Treat dates for CHMP recommendations as ROUGH ESTIMATES ONLY! Readers are advised to pay more attention to the text in the “Link” column with regard to estimated decision dates, rather than the date in the “CHMP recommendation” column. CHMP Recommendation (estimate ONLY). May 1, 2014 at 5:23 am.
admin | BioPharmCatalyst
https://www.biopharmcatalyst.com/author/admin
FDA Calendar – Glossary. BioPharmCatalyst new website to be launched soon latest updates to the Pipeline Database. Aug 12, 2016. Latest updates to the Company Pipeline Database. Aug 10, 2016. BPC August 05 updates: DVAX Advisory Committee meeting set for Nov 16 updates for AUPH CRMD KMDA RIGL. Aug 06, 2016. Updates to the Company Pipeline Database for August 05, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary DVAX 16.73 HEPLIS...Updates t...
61 pipeline updates for 42 companies from May 7 and 8 | BioPharmCatalyst
https://www.biopharmcatalyst.com/2015/05/61-pipeline-updates-for-42-companies-from-may-7-and-8
FDA Calendar – Glossary. 61 pipeline updates for 42 companies from May 7 and 8. May 09, 2015. Latest updates to the Company Pipeline Database. For May 7 and 8, 2015. Refer to the FDA Calendar. ACH-3422 in combination with ACH-3102. HCV Hepatitis C – treatment durations of 6, 8 and 12 weeks. Phase 2 to be initiated 2Q 2015. SVR4 results are expected 2H 2015. Macimorelin Acetate – Macrilen. CRL Nov 5 2014. Announced mid-April 2015 plans to initiate a Phase 3 trial in 2015. Cancer – Endometrial. Agitation i...
Latest updates for INCY PCYC SGEN BMRN CEMP CYTK CYTR EBIO EXEL KYTH LPCN LXRX MDCO NBIX NBS OCRX OGXI OPK THLD THRX TSRO | BioPharmCatalyst
https://www.biopharmcatalyst.com/2015/05/latest-updates-for-incy-pcyc-sgen-bmrn-cemp-cytk-cytk-cytr-ebio-exel-kyth-lpcn-lxrx-mdco-nbix-nbs-ocrx-ogxi-opk-thld-thrx-tsro
FDA Calendar – Glossary. Latest updates for INCY PCYC SGEN BMRN CEMP CYTK CYTR EBIO EXEL KYTH LPCN LXRX MDCO NBIX NBS OCRX OGXI OPK THLD THRX TSRO. May 02, 2015. Latest updates to the Company Pipeline Database. For April 29-May 1 2015. Refer to the FDA Calendar. Ruxolitinib – JANUS 1 and JANUS 2. Cancer – Pancreatic. Phase 3 data for JANUS 1 due 2016. JANUS 2 due at a later date. Cancer – newly diagnosed elderly CLL/SLL patients. Phase 3 data due mid 2015. BRILLIANCE (CLL3002) – IMBRUVICA. Phase 3 initia...
TOTAL PAGES IN THIS WEBSITE
19
Stocks DD...: October 2014
http://stocksdd.blogspot.com/2014_10_01_archive.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Wednesday, October 8, 2014. Stocks DD Opines : A ruling in the Banana Republic creates a brouhaha and How will Ball Street Journal editorialize it? Read, understand and consent to the blog's DISCLAIMER here. By no means,...
Stocks DD...: May 2015
http://stocksdd.blogspot.com/2015_05_01_archive.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Wednesday, May 13, 2015. Stocks DD Opines: The Shareholder Pledge, Shareholder Day and Words of Ethical Wisdom for Board Members. Read, understand and consent to the blog's DISCLAIMER here. Many companies already do annu...
Stocks DD...: Stocks DD Opines & Cites: Biosimilars - Arguably a Big, Complex, Niche Business Opportunity of this Decade in Pharma
http://stocksdd.blogspot.com/2015/11/stocks-dd-opines-cites-biosimilars.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Monday, November 23, 2015. Stocks DD Opines and Cites: Biosimilars - Arguably a Big, Complex, Niche Business Opportunity of this Decade in Pharma. Read, understand and consent to the blog's DISCLAIMER. Biosimilars vs Int...
Stocks DD...: December 2013
http://stocksdd.blogspot.com/2013_12_01_archive.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Monday, December 23, 2013. Stocks DD Cites Ackman's Q4 Investor Letter Update. Read, understand and consent to the blog's DISCLAIMER here. Before proceeding to read the article. Not much info at all other Herbalife.
Stocks DD...: Stocks DD Opines: The Shareholder Pledge, Shareholder Day & Words of Ethical Wisdom for Board Members
http://stocksdd.blogspot.com/2015/05/stocks-dd-opines-ethical-words-of-wisdom.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Wednesday, May 13, 2015. Stocks DD Opines: The Shareholder Pledge, Shareholder Day and Words of Ethical Wisdom for Board Members. Read, understand and consent to the blog's DISCLAIMER here. Many companies already do annu...
Stocks DD...: June 2014
http://stocksdd.blogspot.com/2014_06_01_archive.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Tuesday, June 24, 2014. Stocks DD Cites : Valeant's Rebuttal to Allergan's Rebuttal. Read, understand and consent to the blog's DISCLAIMER here. Before proceeding to read the article. Subscribe to: Posts (Atom). By no me...
Stocks DD...: Stocks DD Cites: 80-Year old Shareholder with significant net worth in FNMA writes letter to FNMA Board
http://stocksdd.blogspot.com/2016/03/80-year-old-shareholder-with.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Friday, March 4, 2016. Stocks DD Cites: 80-Year old Shareholder with significant net worth in FNMA writes letter to FNMA Board. Read, understand and consent to the blog's DISCLAIMER here. JOSHUA J. ANGEL. Follow Stocks D...
Stocks DD...: April 2015
http://stocksdd.blogspot.com/2015_04_01_archive.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Sunday, April 26, 2015. Stocks DD Opines: Investor Relations and some Best Practices. Read, understand and consent to the blog's DISCLAIMER. Before proceeding to read the article. What is Investor Relations? 2 Annual att...
Stocks DD...: March 2016
http://stocksdd.blogspot.com/2016_03_01_archive.html
Read and Consent to Legal Disclaimer- here. Currently covering TARO(long), TSRX CVR(long),APD(long), FNMA(long),MMYT,CEMP,FIATY, AMRN, JCP, MNTA, and BAC.WS.A, HKD, HLF. Shareholders should engage in constructive activism by actively engaging with board to maximize value of their shares. Friday, March 4, 2016. Stocks DD Cites: 80-Year old Shareholder with significant net worth in FNMA writes letter to FNMA Board. Read, understand and consent to the blog's DISCLAIMER here. JOSHUA J. ANGEL. If you like to ...
$MSB.AX, no thanks. I’d rather have miso-soup | FeedingBiotech
https://feedingbiotech.com/2011/06/20/msb-ax-no-thanks-id-rather-have-miso-soup
Full steam ahead for $AVEO. SGPY…where is the Synergy? MSBAX, no thanks. I’d rather have miso-soup. June 20, 2011. Can data since the alliance explain this? What did we learn that we did not know before? On Jan 10, 2011, they announced interim 6-mo data from a controlled 60-pt P2 trial in CHF patients. There have been no cell-related adverse events in any of the 45 patients treated with Revascor , demonstrating that all three doses of the cell therapy product are safe over both the short and medium term.
TOTAL LINKS TO THIS WEBSITE
118
biopharmazie.com
biopharmazie.info
The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).
biopharmazie.org
The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).
Biopharmblog | Pharmaceutical translation Rus -> Eng
Pharmaceutical translation Rus - Eng. Биофармблог поздравляет всех с праздниками! А британские ученые провели ретроспективное обсервационное (наблюдательное? 😀 ) исследование, в котором оценивались факторы, влияющие на приход Санта-Клауса к детям. Happy Holidays! Читать далее →. Где найти тексты по клиническим исследованиям? Источник: Где найти тексты по клиническим исследованиям? Читать далее →. 90% of this cake is missing, while 10% of these donuts are still here. Хочу поделиться с вами своим открытие...
BIOPHARM CANADA REVIEW
Saturday, April 09, 2005. KRC Canada objective is to excel, according to internationally accepted standards of scientific excellence. This article has been published by the International Biopharmaceutical Association www.ibpassociation.org. Please note this article does not give any medical advice. The project is sponsored by Kriger Research - CRO and Training Services ( www.kriger.com. And ClinQua CRO ( www.clinqua.com. Start your Clinical Research Career Now. Clinical Research Associate Program.
Biotech Stocks for investors and traders • BioPharmCatalyst
Keep your ear to the ground with our FREE newsletter including our watch list, weekly review and daily updates. Get Your Free Biotech Newsletter Now. Drug Pipeline Database and Screener. Biotech Stock Weekly Watch List. Daily Biotech Stock Updates. Achieve Life Sciences Inc. Applied Genetic Technologies Corporation. Alpine Immune Sciences Inc. Asterias Biotherapeutics Inc. Common Series A. Actinium Pharmaceuticals Inc. (Delaware). Anavex Life Sciences Corp. Brainstorm Cell Therapeutics Inc. Valeant Pharm...
Anabolic Steroid Powders | Bulk Pure Raw Steroid Powder,Homebrew Steroids Oil,Injectable steroids,Peptides,Bodybuilding Supplements,etc
Animal and Plant Extract. High quality, competitive price, fast delivery, best package, safe shipping and reship policy service gain the trust and praise from the customers all over the world. Let's join hand,go further and win together and make our life better! Buy Anabolic Steroids Raw Trenbolone Acetate Powder. Quality Raw Steroid Powders Dianabol. Anavar Raw Powder Steroid Oxandrolone. Buy Raw Steroids Trenbolone Enanthate Powder. Peptides Hormone Powder GHRP-6.
Home | Biopharm
Skip to main content. Or click here to send an email. C of A and MSDS. Find Multiple Products by Catalog Number. Pharmaceutical intermediaries Biopharm Chemical. Enzyme creation and development Biopharm Chemical. Liposome development Biopharm Chemical. Amino acid development Biopharm Chemical. View All Featured Chemicals. S)-2-(4-(aminomethyl)-1H-1,2,3-triazol-1-yl)-3-carbamoylpropanoic acid. S)-2-(4-( ( 9H-fluoren-9-yl)methoxy)carbonylamino)methyl)-1H-1,2,3-triazol-1-yl)-4-methylpentanoic acid.
午夜电影网__神马电影网
biopharmCMC - BioPharmaceutical Development Consulting - Home
About Dr. Senderoff. Provides consulting services supporting the development and commercialization of biopharmaceutical drug products and medical devices. The consultancy is owned and operated by. Richard I. Senderoff, Ph.D. Who helps clients with their drug product development efforts associated with Chemistry, Manufacturing, and Controls (CMC). Create a free website. Photo used under Creative Commons from ThiagoJ.
BIOPHARM ™ - Colombia ..:: Sitio en Construcción ::..
SOCIAL ENGAGEMENT